

1 **Combined PD-L1 and TIM-3 blockade improves the expansion of fit**
2 **human CD8+ antigen-specific T cells for adoptive immunotherapy**

3
4 Shirin Lak¹, Valérie Janelle¹, Anissa Djedid², Gabrielle Boudreau¹, Ann Brasey^{1,3}, Véronique Lisi², Cédric
5 Carli¹, Lambert Busque^{1,3,4,5}, Vincent-Philippe Lavallée^{2,6,7}, Jean-Sébastien Delisle^{1,4,5}

6
7 ¹ Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada

8 ² Centre de recherche du CHU Sainte-Justine, Montréal, Qc, Canada

9 ³ Biomarker Unit, Centre C3i, Montréal, Qc, Canada

10 ⁴ Department of Medicine, Université de Montréal, Montréal, Qc, Canada

11 ⁵ Hematology-Oncology and Cell therapy Division, Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada

12 ⁶ Department of Pediatrics, Université de Montréal, Montréal, Qc, Canada

13 ⁷ Hematology-Oncology Division, CHU Sainte-Justine CHU Sainte-Justine

14

15 Correspondence to:

16 Jean-Sébastien Delisle MD, FRCPC, PhD
17 Centre de recherche de l'Hôpital Maisonneuve-Rosemont
18 5415, Boul de L'Assomption
19 Montréal, Qc H1T 2M4
20 Canada
21 js.delisle@umontreal.ca

22

23

24 Word count

25 Abstract: 343

26 Main text: 5081

27

28 **Declarations**

29 **Ethics approval and consent to participate.** Informed consent was obtained from all cell donors as
30 detailed in the Method section.

31 **Consent for publication.** All authors have reviewed the final version and agreed with the submission. The
32 corresponding author agrees to pay the publication charges.

33 **Availability of data and material.** As detailed in the Methods section, the genomic data have been
34 deposited for public access and agree to share protocols. All materials used are commercially available.

35 **Competing interest.** The authors have no relevant conflict of interest to disclose.

36 **Funding.** This work was funded by the Leukemia/Lymphoma Society of Canada (grants #622735 and
37 #430053) to JSD.

38 **Authors' contribution.** SL and JSD conceived the study. SL, VJ, AB, CC performed experiments. SL, VJ,
39 AB, AD, GB, VL analyzed data. LB, VPL, JSD oversaw data analysis. SL, VJ and JSD wrote the manuscript.
40 All authors reviewed the manuscript.

41 **Acknowledgments.** The authors are grateful to the volunteer blood donors and Héma-Québec for the
42 leukocytes reduction chamber procurement and handling. We also acknowledge the valuable contribution
43 of Martine Dupuis (flow cytometry and sorting) and the Genome Québec staff for the single-cell RNA-
44 sequencing. SL and VJ are respectively former Cole Foundation and Fonds de recherche du Québec-Santé
45 (FRQS) studentship awardees, JSD and VPL hold FRQS clinician-scientist career awards and JSD is a
46 member of the ThéCell network and of the Canadian Donation and Transplant Research Program
47 (CDTRP).

48

49 List of Abbreviations

50	ACT	Adoptive Cell Therapy
51	APC	Antigen Presenting Cell
52	CCR7	C-C chemokine receptor type 7
53	CD	Cluster of differentiation
54	CDR	Complementarity Determining Region
55	CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
56	CTLs	Cytotoxic T-lymphocytes
57	CTV	Cell Trace Violet
58	CTY	Cell Trace Yellow
59	DC	Dendritic Cell
60	DMSO	Dimethylsulfoxide
61	EBV	Epstein-Barr virus
62	ELISPOT	Enzyme-linked immune absorbent spot
63	FBS	Fetal Bovine Serum
64	FOXP3	Forkhead Box P3
65	Gal-9	Galectin-9
66	GM-CSF	Granulocyte-Macrophage Colony-Stimulating Factor
67	GrzB	GranzymeB
68	HLA	Human Leukocyte Antigen
69	HMGB1	High Mobility Group Protein B1
70	IFN	Interferon
71	Ig	Immunoglobulin
72	IL	Interleukin
73	KLRG1	Killer cell Lectin-like Receptor G1
74	LAG-3	Lymphocyte-Activation Gene 3
75	LRSC	Leuko Reduction System Chamber
76	mAB	Monoclonal Antibody
77	MHC	Major Histocompatibility Complex
78	NGS	Next-generation Sequencing
79	PBMC	Peripheral Blood Mononuclear Cell
80	PBS	Phosphate-buffered saline
81	PD-1	Programmed Cell Death-1
82	PD-L1	Programmed Death Ligand-1
83	PGE2	Prostaglandin E2
84	PHA	T-cell mitogen phytohemagglutinin
85	PMA	Phorbol 12-myristate 13-acetate

86	PS	Phosphatidyl Serin
87	RT	Room Temperature
88	SC-RNA	Singel Cell RNA
89	TAA	Tumor-Associated Antigen
90	TAP	Transporter associated with Antigen Processing
91	Tcm	Central Memory T cell
92	TCR	T-cell Receptor
93	Teff	Effector T cell
94	Tem	Effector Memory T cell
95	TGF- β	Transforming Growth Factor- β
96	TIM-3	T-cell Immunoglobulin and Mucin-domain Containing-3
97	TMB	3,3',5,5'-Tetramethylbenzidine
98	TNF	Tumor Necrosis Factor
99	TSA	Tumor-Specific Antigen
100	Tscm	Stem-cell Like memory T cells
101	WT1	Wilms' tumor suppressor gene1
102		

103 **Abstract**

104 **Background.** The stimulation and expansion of antigen-specific T cells *ex vivo* enables the targeting of a
105 multitude of cancer antigens. However, clinical scale T-cell expansion from rare precursors requires
106 repeated stimulations *ex vivo* leading to T-cell terminal effector differentiation and exhaustion that adversely
107 impact therapeutic potential. We leveraged immune checkpoint blockade relevant to antigen-specific CD8+
108 human T cells to improve the expansion and function of T cells targeting clinically relevant antigens.

109 **Methods.** A clinically-compliant protocol relying on peptide-pulsed monocyte-derived dendritic cells and
110 cytokines was used to expand antigen-specific CD8+ targeting the oncogenic Epstein-Barr virus (EBV) and
111 the tumor associated antigen (TAA) Wilms Tumor 1 (WT1) protein. The effects of antibody-mediated
112 blockade of immune checkpoints applied to the cultures (T-cell expansion, phenotypes and function) were
113 assessed at various time points. Genomic studies including single cell RNA (scRNA) sequencing and T-
114 cell receptor sequencing was performed on EBV-specific T cells to inform about the impact of immune
115 checkpoint blockade on the clonal distribution and gene expression of the expanded T cells.

116 **Results.** Several immune checkpoints were expressed early by *ex vivo* expanded antigen-specific CD8+ T
117 cells, including PD-1 and TIM-3 with co-expression matching evidence of T-cell dysfunction as the cultures
118 progressed. The introduction of anti-PD-L1 (expressed by the dendritic cells) and anti-TIM-3 antibodies in
119 combination (but not individually) to the culture led to markedly improved antigen-specific T-cell expansion
120 based on cell counts, fluorescent multimer staining and functional tests. This was not associated with
121 evidence of T-cell dysfunction when compared to T cells expanded without immune checkpoint blockade.
122 Genomic studies largely confirmed these results, showing that double blockade does not impart particular
123 transcriptional programs or patterns on TCR repertoires. However, our data indicate that combined
124 blockade may nonetheless alter gene expression in a minority of clonotypes and have donor-specific
125 impacts.

126 **Conclusions.** The manufacturing of antigen-specific CD8+ T cells can be improved in terms of yield and
127 functionality using blockade of TIM-3 and the PD-L1/PD-1 axis in combination. Overcoming the deleterious
128 effects of multiple antigenic stimulations through PD-L1/TIM-3 blockade is a readily applicable approach for
129 several adoptive-immunotherapy strategies.

130

131 **Background**

132 The vast majority of potentially actionable cancer antigens are major histocompatibility (MHC)-bound
133 peptides. These include tumor-specific antigens (TSA) resulting from mutated proteins or aberrantly
134 expressed regions of the genome, tumor associated antigens (TAA) that come from abnormally expressed
135 self-proteins and finally, non-self peptides best described in the setting of virus-associated cancers or
136 allogeneic stem cell transplantation^{1 2}. While it has been possible to isolate TSA or TAA-specific T-cell
137 receptors (TCR) and manufacture TCR-transgenic T cells for adoptive immunotherapy, this approach faces
138 numerous technical hurdles and is currently available only for a minority of relevant cancer antigens³.
139 Several effective adoptive immunotherapy strategies rely on the *ex vivo* expansion of native antigen-specific
140 T cells, enabling the targeting of a vast array of antigens. However, the expansion of large numbers of
141 antigen-specific T cells requires repeated antigen exposure (through co-culture with antigen-presenting
142 cells – APC) and stimulatory cytokines, potentially leading to T-cell dysfunction (terminal effector
143 differentiation and exhaustion) and poor performance following adoptive transfer⁴⁻⁶.

144
145 Alternatively, the endogenous cancer-reactive T-cell repertoire can be mobilized through the systemic
146 administration of antibodies that prevent signaling from inhibitory co-signaling receptors present on the
147 surface of exhausted T cells^{7 8}. Such "immune-checkpoint" blockade, targeting most commonly Cytotoxic
148 T-lymphocyte-associated protein 4 (CTLA-4) and Programmed death-1 (PD-1) on T cells (or its
149 corresponding primary ligand, Programmed death-ligand 1 - PD-L1), is now the cornerstone of therapeutic
150 regimes against several types of neoplasia including advanced melanoma and lung cancer⁹. As
151 dysfunctional cancer-reactive T cells often express multiple negative co-signaling molecules, a strategy has
152 been to use combined approaches with the caveat that increased response may come with more immune-
153 related toxicities¹⁰. *Ex vivo* expanded T cells express inhibitory receptors, and PD-L1/PD-L2 silenced
154 antigen-presenting dendritic cells have been shown to improve the expansion and function of antigen-
155 specific T cells *ex vivo*¹¹, thus providing a solid rationale to leverage immune checkpoint blockade to
156 improve T-cell manufacturing for adoptive immunotherapy.

157

158 We show herein that the *ex vivo* expansion of CD8+ T cells specific for a viral antigen and a TAA is
159 enhanced by using combined PD-L1 and T-cell immunoglobulin and mucin-containing protein-3 (TIM-3)
160 blockade, while single blockade of either receptor fails to improve T-cell expansion. The generated antigen-
161 specific T cells did not show phenotypic and functional evidence of exhaustion or terminal effector
162 differentiation. This was corroborated with single-cell RNA (sc-RNA) and VD(J) sequencing, which revealed
163 that dual immune checkpoint blockade can impact T-cell gene expression in a donor and clonotype-
164 dependent fashion. Taken together, our results show that dual PD-L1/TIM-3 blockade during *ex vivo*
165 expansion can yield large quantities of fit human antigen-specific T cells for adoptive immunotherapy.

166

167 **Methods**

168 **Donors and cellular procurement**

169 Peripheral blood mononuclear cells (PBMCs) from HLA-A0201 expressing volunteer donors were isolated
170 using Ficoll-Hypaque gradient (STEMCELL Technologies) from fresh whole blood (collected by
171 venipuncture) or leukoreduction system chambers provided by Héma-Québec (LRSCs) as previously
172 described^{12 13}. All donors provided written informed consent, and all the experiments were approved by the
173 Héma-Québec and Hôpital Maisonneuve-Rosemont Research Ethics Committees. Recovered PBMCs
174 were either used immediately for experiments or resuspended in freezing media (90% fetal bovine serum
175 and 10% dimethyl sulfoxide (DMSO)), transferred to Mr. Frosty containers (NALGENE™ Cryo 1⁰C freezing
176 container), and stored in vapor-phase liquid nitrogen for future use.

177 **Dendritic Cells (DCs) differentiation and antigen pulsing**

178 Monocyte isolation and DC differentiation have been generated as previously described⁴. Briefly,
179 monocytes were obtained using the adherence method whereby PBMCs were plated in adherent plastic
180 plates (Sarstedt) in media (X-Vivo 15 medium (LONZA) supplemented with 5% human serum, 2 mM L-
181 glutamine and 1mM Sodium Pyruvate (Gibco), 1000 U/ml (100 ng/ml) IL-4 and 800 U/ml (50ng/ml) GM-
182 CSF (Both from STEMCELL technologies)) and incubated in a CO₂, 37°C incubator for 7 days. On day 4,
183 media was replaced with fresh media supplemented with IL-4 and GM-CSF. On day 7, DCs were matured
184 with maturation media containing 1000 U/ml (100 ng/ml) IL-4, 800 U/ml (50ng/ml) GM-CSF (Both from
185 STEMCELL technologies), 10 ng/ml TNF- α (STEMCELL technologies), 1 μ g/ml PGE2 (SIGMA), 10 ng/ml
186 IL-1 β (Feldan), 100 ng/ml IL-6 (Miltenyi Biotec) and loaded with desired peptide (1 μ g/mL LMP2₄₂₆₋₄₃₄
187 (CLGGLLTMV) or 1 μ g/mL WT₁₃₇₋₄₅ (VLDFAPPGA), both from JPT Peptides. Lastly, DC media was
188 supplemented with IFN- γ 1000U/ml (Feldan) for the last 24 hours of culture.

189 **Ex Vivo expansion of antigen-specific T cells**

190 Antigen-specific T cells were stimulated using a clinically compliant protocol as previously described (⁴ and
191 www.clinicaltrials.gov NCT03091933) from 15x10⁶ PBMCs and expanded through multiple weekly
192 stimulations using irradiated (40 Gy) autologous, peptide-loaded monocyte-derived DCs at a 1:10

193 (DC:PBMC) in a G-Rex6® Well Plate vessel (Wilson Wolf Manufacturing, New Brighton, MN). Our complete
194 T-lymphocyte culture (CTL) media (Advanced RPMI 1640, 10% human serum, 1X L-glutamine(Gibco)) was
195 supplemented with the following cytokines; week 1: IL-21 (30 ng/mL) and IL-12 (10 ng/ mL) (Both from
196 Feldan), week 2: IL-21, IL-2 (100 IU/mL), IL-7 (10 ng/mL) and IL-15 (5 ng/mL) (STEMCELL Technologies),
197 subsequent weeks: IL-2, IL-7 and IL-15. Medium, including cytokines, was refreshed every 3 to 4 days, and
198 specific T cell cultures were restimulated once every week with peptide-loaded monocyte-derived DCs
199 (moDCs). Cell concentration was adjusted to 1:10 ratio each week. When indicated, cultures were
200 supplemented with 20 µg/ml of anti-PD-L1 blocking mAb (BioXcell, 29E.2A3) or/and 10 µg/ml of anti-TIM3
201 blocking mAb (Biolegend, F38-2E2) with all media changes. Respective isotype antibodies, mouse IgG1
202 (BioXcell, MOPC-21) and InVivoMAb mouse IgG2b (BioXcell, MPC-11), were used at the same
203 concentration where indicated. All cell cultures were performed in monitored incubators (37°C in 5% CO₂
204 and 5% air humidity). Cell viability and cell counts were assessed by the countess automated cell counter
205 (Invitrogen) using trypan blue (Invitrogen) at a 1:1 ratio with the cellular suspension in cell counting chamber
206 slides (Invitrogen-C10283).

207 **Flow cytometry**

208 The phenotype of mature DCs was assessed by cell surface expression of the following markers (antibody
209 clone in parenthesis) CD80 (L307.4), CD86 (2331, FUN1), HLA-ABC (W6-32), CD11c (3.9), CD19 (HIB19)
210 (all from BD Biosciences), HLA-DR (LN3), and CD83 (HB15e) (both from Invitrogen). To detect antigen-
211 specific CD8⁺ T cells, up to 10⁶ cells were suspended in phosphate-buffered saline (PBS) plus 2% fetal
212 bovine serum (FBS) and stained with allophycocyanin (APC) labeled tetramers, MHC-Dextramers A*0201
213 (Immudex,), for 10 minutes in the dark at 4°C. For additional cell surface markers and phenotyping, cells
214 were stained with following antibodies: CD3 (SKY7), CD3 (UCHT1), CD8 (SK1), CD45RO (UCHL1),
215 CD45RA (5H9), CCR7 (150503), LAG3 (T47.530), and CD4 (RPA-T4) all from BD Biosciences; CD62L
216 (DREG-56), TIM3 (F38-2E2), PD-1 (EH12.2H7), KLRG1 (2F1/KLRG1), CD57 (HCD57), and PD-L1
217 (29E.2A3) from Biolegend and CD8 (RPA-T8) and CD244 (eBioDM244) from Invitrogen. Staining was
218 performed at room temperature (RT) in the dark for 30 minutes. According to the manufacturer's instructions
219 for intracellular detection of cytokines, cells were permeabilized, fixed and stained using the Foxp3 /

220 Transcription Factor Staining Buffer Set (eBioscience). Before the fixation step, up to 10^6 cells were
221 stimulated to produce cytokines with the indicated peptide (0.5 $\mu\text{g}/\text{ml}$) (test condition) or PMA (50 ng/mL)-
222 ionomycin (500 ng/mL) (Sigma-Aldrich) (positive control) and an irrelevant peptide (HLA-A0201 restricted
223 but not used as a stimulator in the culture-negative control) for 4 h at 37°C . Cells are suspended in CTL
224 media plus brefeldin A (Biolegend) to block the secretion of cytokines during the stimulation period. Cells
225 were then harvested and stained for cell-surface markers, including CD3, CD4, and CD8 in 4°C for 20
226 minutes. Next, fixed and permeabilized cells were stained with intracellular cytokine detection antibodies;
227 IFN- γ (4S.B3), IL-2 (MQ1-17H12), and TNF- α (Mab11) all purchased from BD Biosciences) and Ki67 (ki-
228 67) from Biolegend at RT for 20 minutes. Cell acquisition was performed on a Fortessa or LSR II flow
229 cytometer (BD Biosciences), and data were analyzed with Flowlogic Software (inivai).

230 **IFN- γ Enzyme-linked immune-spot (ELISpot)**

231 ELISPOT assays were performed using Human IFN- ELISpot^{PLUS} kit (MABTECH), following the
232 manufacturer's instruction. Briefly, pre-coated wells were washed 5 times with sterile PBS (200ul/well), then
233 incubated with CTL media (100 ul/well) for 30 minutes in a 37°C incubator with 5% CO_2 . Cultured cells
234 were added (5×10^4) to wells in duplicates and then stimulated with anti-CD3 mAb (positive control),
235 irrelevant peptide (specificity control), and test peptide. After an 18-hour incubation the plates were washed
236 with PBS (200ul/well) 5 times and incubated with detection antibody (7-B6-1-biotin, 1ug/ml, 100 ul/well) for
237 2 hrs at RT. Next, plates were washed with PBS (200ul/well) 5 times and incubated with streptavidin-HRP
238 (100 ul/well) for 1 hr at room temperature. Lastly, plates were rewashed as above, and TMB substrate
239 solution (100 ul/well) was added in darkness. Color development was stopped by washing extensively in
240 deionized water after distinct spots emerged. Plates were dried, and the dots were counted using ELISpot
241 reader (vSpot Reader Spectrum, AID).

242 **Flow Cytometry-based Cytotoxicity assay**

243 Flow cytometry-based cytotoxicity assay was performed using either Cell Trace Violet (CTV) or Cell Trace
244 Yellow (CTY) (Invitrogen Life Technologies) labeled LMP2₄₂₆₋₄₃₄ pulsed as target cells as described
245 before¹⁴. Briefly, target cells were prepared by stimulating autologous PBMCs with the T-cell mitogen
246 phytohemagglutinin (PHA) (3×10^6 PBMCs/mL were incubated in T-cell media with 20 $\mu\text{g}/\text{mL}$ PHA) for 3

247 days at 37 °C and 5% CO₂. Peptide pulsed (or not pulsed) target cells were co-cultured with LMP2-specific
248 T cells at various ratios for 4 hours in CTL plus 10% horse serum. Unpulsed target cells alone were used
249 as control. After incubation, cells were harvested, stained with LIVE/DEAD Fixable Aqua Dead Cell Stain
250 Kit, Life Technologies) according to manufacturers' instructions and viable target, cells were quantified by
251 flow cytometry using Flow Count Beads (Beckman Coulter). Cytotoxicity was calculated by comparing the
252 percentage of viable target cells in test conditions relative to control (100 - (Target cell alive/ Target cell
253 alone) × 100).

254 **Single-cell RNA sequencing and High-throughput TCR sequencing**

255 At indicated time points, T cells were sorted based on MHC-Dextramer and CD8 staining using FACS Aria
256 III (DB Biosciences). Post sorted purity of the sorted population was 94%. A fraction of the sorted antigen-
257 specific T cells was subjected to both VDJ and transcriptome sc-RNA sequencing at the Genome Quebec
258 facilities. Briefly, cells were counted and viability assessed using a hemocytometer and Trypan Blue. The
259 targeted cell recovery was set at 6000 cells and libraries were prepared using the kits Chromium Next GEM
260 Single Cell 5' Kit v2 and Chromium Single Cell Human TCR Amplification Kit (10x Genomics inc.), as per
261 the manufacturer's recommendations. Libraries were quantified using the Kapa Illumina GA with Revised
262 Primers-SYBR Fast Universal kit (Kapa Biosystems). Average size fragment was determined using a
263 LabChip GX (PerkinElmer) instrument. The 10X Single cells 5' libraries were sequenced on Illumina HiSeq
264 4000 PE28x98 while the 10X Single Cells VDJ (Human T) libraries were sequenced on Illumina HiSeq 4000
265 PE150. The Illumina control software was HCS HD 3.4.0.38, the real-time analysis program was RTA v.
266 2.7.7. bcl2fastq2 v2.20 was then used to demultiplex samples and generate fastq files. Reads were aligned
267 to GRCh38 genome assembly, gene expression matrices generated, and clonotype identification
268 performed using CellRanger v3.0.2. The resulting gene expression matrices were normalised by total UMI
269 counts per cell multiplied by the median UMI count per cell and natural-log transformed using Scanpy v1.4¹⁵.
270 PhenoGraph¹⁶ clustering was applied with k=20 and clusters with a median mitochondrial fraction greater
271 than 0.2 were filtered out. Clonotypes were defined by nucleotide sequences of alpha and beta chains. In
272 order to remove potential doublets, we restricted our analysis to cells in which exactly one alpha and one
273 beta chain were identified and retained only the most abundant clonotype for each alpha and beta chain.

274 The number of retained cells per sample is provided in Table S1. After filtering, individual count matrices
275 were combined and normalized and log transformed together for downstream analyses.

276

277 For expression analysis, only abundant clonotypes in each donor were retained. Abundant clonotypes are
278 defined as those identified in at least 10 cells in each condition and at a frequency over all cells of a donor
279 greater than 0.01. Pathway expression is defined as the log₂ of the sum of the normalized gene expression
280 for every gene in the pathway. Genes associated with each pathway are listed in Table S2.

281

282 Significance of the changes in pathway expression between the control and double blockade conditions
283 was assessed using a Mann-Whitney U test. The p-values returned for each pathway comparison were
284 contrasted with those obtained when comparing the expression in the DDB and CTRL conditions to those
285 in 1000 random gene sets with the same number of genes with identical expression distribution as the
286 pathway of interest. For each random gene set, we computed the p-value of the comparison using the
287 Mann-Whitney U test. We report the percentile ranking of the p-value in the true pathway compared to the
288 p-values obtained from the random gene sets.

289

290 Bulk TCR repertoire profiling was performed from sorted multimer positive and negative CD8⁺ T-cell RNA
291 preserved in Trizol reagent (Invitrogen) using Next-Generation Sequencing (NGS) targeting the
292 hypervariable complementarity-determining region 3 (CDR3) of the T cell receptor beta chain (TCR β).
293 TRIzolTM extracted RNA in combination with the PureLink RNA mini and microcolumn system (Thermo
294 Fisher), quantified by UV spectrophotometry (Tecan), and QC was completed on Bioanalyzer chip (Agilent).
295 TCR β amplicon libraries were prepared from 25 ng total RNA with the OncomineTM TCR Beta-SR Assay
296 for RNA (ThermoFisher Scientific). The TCR β libraries obtained were quantified on the ViiA 7 Real-Time
297 PCR System with the Ion Library Taqman Quantitation kit (Thermo Fisher). NGS was completed on the Ion
298 S5 semiconductor platform using an Ion 540 chip, prepared with the Ion Chef System (all from Thermo
299 Fisher). TCR β repertoire analysis was completed using the Ion Reporter Software (Thermo Fisher) and
300 Immunarch package¹⁷ analyses using R software. The data can be found in the Gene Expression Omnibus
301 (GSE182537 and GSE181682).

302 **Statistical Analysis**

303 Statistical significance was analyzed were with the R software, version 4.0.4. Multiple group comparisons
304 were performed using one-way ANOVA and Turkey post hoc test or the Kruskal-Wallis test with the Holm
305 procedure to correct for multiple testing (if ANOVA requirements were not met). Paired Wilcoxon-Mann-
306 Whitney tests were performed for two-group comparisons. p values of 0.05 or less were considered
307 significant.

308

309 **Results**

310 **Multiple stimulations are detrimental to antigen-specific T-cell expansion *ex vivo***

311 Antigen-specific T cells were stimulated using moDCs loaded with the peptide LMP2₄₂₆₋₄₃₄ (CLGGLLTMV),
312 which is an HLA-A0201 restricted antigen from the oncogenic Epstein-Barr virus (EBV). Weekly *ex vivo*
313 stimulations were performed in cytokine supplemented media, and antigen-specific expansion was
314 assessed before each stimulation. While overall T-cell expansion progressed following each of four
315 stimulations (albeit at limited pace after day 14 and two stimulations), the percentage and absolute number
316 of antigen-specific CD8 T cells, as identified by fluorescent HLA-0201/ LMP2₄₂₆₋₄₃₄ multimer, stagnated
317 despite additional stimulations (Figure 1A-C). Further, this halted growth was matched with a gradual
318 change in phenotype. The predominance of central memory (T_{cm}) differentiation profile at day 14 evolved
319 towards an effector memory (T_{em}) and effector (T_{eff}) differentiation phenotype on days 21 and 28 (Figure
320 1D). These results were anticipated as serial T-cell stimulations have been associated with the development
321 of effector T cells that gradually lose their capacity to expand and persist after adoptive transfer⁶. The
322 expression of the inhibitory receptors related to T-cell exhaustion (PD-1, TIM-3, and to a lesser extent LAG3
323 and 2B4) was substantial on a significant fraction of antigen-specific T cells at day 14, with little modulation
324 over time in culture (Figure 1E). However, the fraction of cells showing dual expression of PD-1 and TIM-3
325 increased with repeated stimulation (Figure 1F) in line with the development of CD8⁺ T-cell exhaustion¹⁸⁻
326 ²⁰. Phenotyping of the moDCs revealed prevalent expression of corresponding PD-1 and TIM-3 ligands,
327 (respectively PD-L1 and CEACAM-1/Galectin 9) (Figure 1G). These results confirm and extend previous
328 data, suggesting that the early and persistent expression of PD-1 and TIM-3 by CD8⁺ T cells, along with
329 the expression of their ligands by stimulating DCs, may represent a significant hurdle for the expansion of
330 antigen-specific T cells for immunotherapy^{18 19}.

331

332 **Combination of PD-L1/PD-1 axis and TIM-3 blockade significantly increases antigen-specific CD8⁺** 333 **T-cell expansion**

334 In order to assess if immune checkpoint blockade during *ex vivo* expansion may improve antigen-specific
335 T-cell yield, anti-PD-L1, anti-TIM-3, or both were added to the culture media at the beginning of culture and
336 with all media changes. Cell counts at day 14, and even more strikingly at day 21, revealed that the double

337 blockade condition significantly increased T-cell expansion relative to control (no checkpoint blockade) and
338 the single blockade groups (Figure 2A). This translated into a marked increase in LMP2₄₂₆₋₄₃₄-specific T-
339 cell yield in the dual blockade condition despite no gain (and in fact a decline at day 14) in the percentage
340 of multimer positive CD8⁺ T cells (Figure 2B-C). In contrast, the single blockade of PD-L1 or TIM-3 offered
341 no advantage at any time point. The phenotypic assessment of LMP2₄₂₆₋₄₃₄-specific T cells revealed no
342 statistically significant difference in the percentages of T_{cm}, T_{em}, and T_{eff} and no difference in PD-1 or
343 TIM-3 expression (Figure 2D-E). However, the percentage of T cells expressing the inhibitory receptors
344 LAG3 and 2B4 was lower in the combined relative to the control condition. Hence, dual PD-L1 and TIM-3
345 blockade increased T-cell growth without conferring phenotypic changes associated with increased T-cell
346 dysfunction.

347
348 It is known that TIM-3 has a dual function. TIM-3 is transiently upregulated at intermediate levels on
349 activated T cells and confers activation signals²¹. However, in settings of chronic stimulation in the presence
350 of its ligands, TIM-3 inhibits T-cell activation and behaves as a *bona fide* immune checkpoint. We, therefore,
351 slightly modified our protocol to introduce TIM-3 blockade at day 7, a week after the first stimulation
352 (hereafter designated as delayed double blockade-DDB), with the expectation that it would further improve
353 antigen-specific T-cell yield. Compared to the dual blockade started on day 0, DDB slightly increased total
354 T-cell expansion at day 21 and more convincingly following an additional antigenic stimulation (day 28)
355 (Figure 3A). Moreover, the DDB approach increased the percentage of LMP2₄₂₆₋₄₃₄-specific T cells at all
356 time points relative to the control condition (no blocking antibodies used), including at day 14 which was
357 not the case when PD-L1 and TIM-3 blockade were both applied at day 0 (Figure 3B). Absolute antigen-
358 specific counts were also increased in the DDB relative to the control condition (significant on days 21 and
359 28) (Figure 3C). Finally, DDB did not impact T-cell differentiation or exhaustion marker expression (Figure
360 3D-E). Independent cultures using isotype control antibodies confirmed the specific effects of anti-PD-L1
361 and anti-TIM-3 antibodies on the antigen-specific T-cell expansion (Supplementary Figure 1). We conclude
362 that combined blockade of the PD-L1/PD-1 axis and TIM-3 can be incorporated in *ex vivo* cultures to
363 increase antigen-specific CD8⁺ T-cell yield for adoptive immunotherapy without altering T-cell phenotypes.
364

365 **Double immune checkpoint blockade generates functional antigen-specific T cells**

366 Dual PD-L1 and TIM-3 blockade increases antigen-specific CD8⁺ T-cell expansion in culture without
367 altering T-cell phenotypes suggesting comparable functionality. Intracellular cytokine secretion
368 measurements and ELISpot assays at day 28 confirmed that a higher proportion of T cells were reactive
369 upon LMP2₄₂₆₋₄₃₄ peptide re-exposure in the DDB condition relative to control (no checkpoint inhibition)
370 (Figure 4A-B). This was also generally the case when DDB was compared to double immune checkpoint
371 blockade administered at day 0 (statistically significant in ELISPOT data at day 28). We thus pursued our
372 functional assessments comparing DDB with the control condition. As further indication of increased
373 functionality, a greater fraction of antigen-specific T cells expanded in the DDB condition relative to control
374 expressed the proliferation marker Ki-67 and upon peptide re-exposure, more DDB exposed T cells
375 displayed evidence of cytotoxic potential (surface CD107a and intracellular granzyme B expression) (Figure
376 4C-D). This was corroborated with cytotoxicity assays showing that T cells from the DDB condition were
377 highly effective, especially at low effector:target ratios (Figure 4E-F). Importantly, in all our assays,
378 combined PD-L1 and TIM-3 blockade did not lead to increased non-specific (off-target or spontaneous)
379 cytokine release or cytotoxicity. Thus, dual immune checkpoint inhibition expands T-cell products with
380 specific and augmented antigen reactivity.

381

382 **PD-L1/TIM-3 blockade imparts no consistent gene expression signatures to expanded antigen-**
383 **specific CD8⁺ T cells**

384 To gain more insight into the biological impacts of double immune checkpoint blockade on antigen-reactive
385 T cells, we submitted sorted day 28 multimer-positive T cells from three donors to paired transcriptome and
386 TCR alpha-beta single-cell RNA sequencing (scRNA-Seq). Gene expression was compared across donor,
387 condition (no checkpoint blockade vs. DDB) and clonotypes. Global gene expression patterns across the
388 three donors revealed strong donor-specific clustering (Figure 5A). The impact of DDB on gene expression
389 for each donor antigen-specific T cells, was assessed using published human T-cell gene sets²². This
390 enabled a detailed assessment of T-cell activation, proliferation, terminal differentiation, exhaustion and
391 metabolism-associated gene expression as these processes are likely to be impacted by DDB. Overall,
392 when every T cells from each condition were compared, no consistent change of gene expression signature

393 could be identified across all donors (Figure 5B). We next evaluated whether clonotype-specific signatures
394 could be identified. The sequencing of the VD(J) regions revealed that the LMP2₄₂₆₋₄₃₄ specific T cells were
395 highly oligoclonal in all donors and conditions (1-4 clones representing more than 80% of all cells – Figure
396 5C and Supplementary Table 3). Most dominant clonotypes were shared between experimental conditions
397 (albeit at different frequencies for Donor 2) and a few clonotypes were shared between donors
398 (Supplementary Table 3). We next analyzed the expression of several pathways in the abundant clonotypes
399 (defined as those identified in at least 10 cells and representing at least 1% of the repertoire in both the
400 DDB and control conditions from the same donor). Similar to comparisons involving all clonotypes, no
401 consistent pattern was found across donors when comparing the DDB versus control condition on a per
402 clonotype basis (Figure 5D). Interestingly, our data unveiled divergent gene expression patterns for one
403 clonotype (Clonotype 3) which was shared by Donor 1 and 2. Relative to its counterpart in the control
404 condition, Donor 1 Clonotype 3 in the DDB condition expressed higher levels of genes related to T-cell
405 exhaustion/differentiation and had a lowered expression of genes associated with T-cell proliferation. The
406 same clonotype in the DDB condition from Donor 2 had, on the contrary, an increased expression of the
407 genes associated with T-cell activation without any transcriptional changes related to T-cell dysfunction (T-
408 cell exhaustion, terminal differentiation, low proliferation). This suggests that donor rather than clonotype
409 related features may determine T-cell outcomes following DDB.

410
411 To assess whether clonotype-specific transcriptional signatures may impact their expansion and clonal
412 hierarchy within the cultures, we used bulk mRNA collected from sorted multimer negative and positive
413 CD8+ T cells at day 21 and 28 from the same donors. RNA of suitable quality was obtained for 23 out of a
414 potential of 24 samples (the multimer-positive fraction of the control condition from Donor 3 had to be
415 excluded) and subjected to complementary determining region 3 (CDR3) region sequencing of the T-cell
416 receptor-beta chain (TCR β). Day 28 multimer-positive T-cell CDR3 sequencing matched very well paired
417 VDJ sequencing of single cells (Supplementary Figure 2), confirmed the oligoclonality of the multimer-
418 positive T cells at both day 21 and 28 and revealed that TCR repertoire diversity in the multimer-negative
419 T cells was not affected by DDB (Figure 6A). Further, the multimer positive and negative fractions had
420 limited overlap (Supplementary Figure 3), suggesting that sorting effectively separated most CD8+ antigen-

421 specific cells from the rest of the T cells in culture. Clonotype hierarchy among multimer-positive T cells at
422 day 21 and day 28 showed no consistent pattern of evolution in DDB relative to the control condition (Figure
423 6B-C). However, the proportion of certain clonotypes in these fractions (both DDB and control) varied
424 greatly (>20%) between day 21 and 28. This was notably the case for Clonotype 3 from Donor 1 in the DDB
425 condition, which declined markedly from day 21 to day 28, whereas this clonotype's abundance did not
426 change significantly between day 21 to 28 of DDB exposure in Donor 2 (Figure 6B). We wondered if the
427 clonotypes with altered abundance between day 21 and day 28 in the same donor and condition displayed
428 a specific transcriptional profile. In general, weak changes in transcriptional signatures were detected when
429 comparing a given clonotype and experimental condition between day 28 and day 21. In the DDB condition,
430 clonotype 3 of Donor 1, which showed a decreased abundance from day 21 to day 28, had a higher
431 expression of genes related to T-cell activation, differentiation and exhaustion. This effect seems to be
432 clonotype and donor specific but not condition specific since a similar behavior is seen in the control
433 condition in clonotype 2 of Donor 3 (Figure 6D). Taken together these data show that DDB has limited
434 impact on the clonal diversity of the expanded T cells overtime. The proportion of isolated clones can
435 nonetheless fluctuate in line with their gene expression signatures at day 28. We noticed a weak trend of
436 increased expression of genes related to exhaustion in clonotypes with decreased abundance at day 28
437 and a rise in the expression of genes related to proliferation in clonotypes with an increased abundance at
438 day 28, irrespective of experimental conditions. Globally, these results suggest that DDB confers no
439 consistent transcriptional features to expanded antigen-specific CD8⁺ antigen-specific T cells but may alter
440 activation/dysfunction, cell cycle and metabolic processes in a clonotypes and donor-dependent fashion.

441

442 **The benefits of dual PD-L1 and TIM-3 blockade extend to TAA-specific T cells**

443 The EBV-derived LMP2₄₂₆₋₄₃₄ antigen stimulates a memory T-cell repertoire in more than 90% of adults²³.
444 The *ex vivo* expansion of naïve T cells is generally considered more challenging for several reasons (size
445 of the repertoire, amount of stimulation required, etc.). We, therefore, sought to determine the impact of
446 dual PD-L1/TIM-3 blockade in the priming and expansion of naïve T cells. It was previously shown that
447 CD8⁺ T cells specific against Wilm's tumor 1 (WT1) derived peptides, a clinically relevant tumor-associated
448 antigen (TAA), are phenotypically naïve in healthy individuals²⁴ but can be expanded from a majority of

449 such donors^{25 26}. Volunteer donor T cells were stimulated with an HLA-0201 restricted WT1 peptide (WT1₃₇₋
450 ₄₅) using the same stimulation/expansion conditions for LMP2₄₂₆₋₄₃₄ specific T cells. Figure 7A-C shows that
451 WT1-specific T cells expanded following a similar pattern as LMP2₄₂₆₋₄₃₄-specific T cells. The expansion,
452 percentages and number of antigen-specific cells as well as their cytokine secretion were improved in the
453 DDB condition relative to cultures without immune checkpoint blockade, again without altering T-cell
454 differentiation patterns or exhaustion marker expression (Figure 6D-G). We conclude that our results
455 obtained with LMP2₄₂₆₋₄₃₄ extend beyond virus-specific memory T-cell expansion and that double PD-
456 L1/TIM-3 immune checkpoint blockade can improve the expansion of functional TAA-specific CD8⁺ T cells
457 from naïve repertoires.
458

459 Discussion

460 The stimulation and expansion of antigen-specific T cells for adoptive immunotherapy is an attractive
461 strategy to target a wide variety of cancer antigens. However, T-cell expansion is limited by the expression
462 of inhibitory receptors and the development of T-cell dysfunction. We confirmed and extended previous
463 studies revealing that immune checkpoint receptors are expressed on repeatedly activated T cells and that
464 their corresponding ligands can be present on antigen-presenting cells used *ex vivo*. Co-expression of PD-
465 1 and TIM-3 has been used to describe highly exhausted CD8⁺ T cells, and combined blockade of these
466 receptors in murine models has previously been shown to improve tumor control relative to single
467 blockade^{18 19 27}. We show that antibody-mediated immune checkpoint blockade targeting PD-1 or TIM-3
468 alone is insufficient to improve CD8⁺ T-cell expansion while the combination improves T-cell expansion and
469 antigen-specific reactivity. These data confirm the synergistic potential of immune checkpoint blockade and
470 the particular relevance of TIM-3 and PD-1 as inhibitory receptors in CD8⁺ T cells¹⁹. The reasons for this
471 synergistic effect might be due to the mobilization of different signaling intermediates by the two receptors.
472 While PD-1 relies on the recruitment of SHP phosphatases to mediate its effects (as for several other
473 negative co-stimulatory molecules), TIM-3 uses Bat3 and Fyn for its stimulatory and inhibitory effects,
474 respectively. We reasoned that delaying TIM-3 blockade by one week after the start of the culture even in
475 the presence of TIM-3 ligands on APC would be beneficial, given previous experimental evidence that TIM-
476 3 provides activation signals following a first T-cell stimulation^{28 29}. This contrasts with PD-1, which conveys
477 inhibitory signals in both exhausted T cells and early after activation³⁰, justifying the use of anti-PD-L1 at
478 culture initiation. We realize that several refinements may be required to fully leverage the potential
479 agonistic/antagonistic effects of TIM-3 on T-cell activation and expansion and determine whether anti PD-
480 L1/PD-1 blockade may also be improved by altering the timing of the inhibition. In addition, whether dual
481 PD-L1/TIM-3 blockade improves T-cell expansion and function across multiple types of T-cell
482 manufacturing protocols should be tested, just like further combinations with blockade of additional
483 inhibitory receptors. Nonetheless, our work provides a new strategy for T-cell expansion and offers novel
484 biological insights on the effects of PD-L1/PD-1 axis and TIM-3 blockade in human antigen-specific T-cell
485 clonotypes submitted to multiple antigenic stimulations.

486

487 Our data support that sustained dual PD-L1/TIM-3 blockade through several rounds of antigenic
488 stimulations provides ongoing benefits without exacerbating T-cell dysfunction or curbing expansion as
489 inferred by previous studies of using inhibitory receptor gene deletion³¹. This was assessed through
490 phenotyping, functional assays, and gene expression in single cells. Our results indicate that antigen-
491 specific CD8⁺ T cells expanded under combined TIM-3/PD-L1 blockade are functional as well as specific
492 and that their clonal composition is generally stable in time and relative to their counterpart not exposed to
493 immune checkpoint blockade. It has been reported that immune checkpoint blockade *in vivo* can shape the
494 T-cell repertoire³²⁻³⁴. Thus, from a perspective of T-cell therapy, it was essential to define whether an
495 intervention during *ex vivo* T-cell expansion alters the clonal identity of the cellular product. While we did
496 not observe consistent effects of PD-L1/TIM-3 blockade on T-cell transcriptome or clonotype distribution,
497 altered transcriptional profiles in a clonotype and donor-dependent manner nonetheless suggests that
498 immune checkpoint blockade in adoptive T-cell therapy may require personalization.

499

500 Further work will be required to understand why some clonotypes may be more susceptible to
501 differentiation/exhaustion following immune checkpoint blockade (previous activation/proliferation history,
502 differentiation status at the beginning of checkpoint blockade, etc). Nevertheless, our data suggest that
503 even after 28 days in culture, the antigen-specific T cells are highly functional, with a third expressing Tcm
504 markers. This indicates that antigen-specific T cells generated in high numbers after dual immune
505 checkpoint blockade could further expand after transfer and likely respond to further immune checkpoint
506 blockade administered *in vivo*.

507

508 We conclude that dual PD-L1/TIM-3 blockade is a readily applicable strategy to improve the expansion of
509 functional antigen-specific CD8⁺ T cells expansion *ex vivo* for adoptive immunotherapy.

510


511 References

- 512 1. Janelle V, Rulleau C, Del Testa S, et al. T-Cell Immunotherapies Targeting Histocompatibility and Tumor
513 Antigens in Hematological Malignancies. *Front Immunol* 2020;11:276. doi:
514 10.3389/fimmu.2020.00276
- 515 2. Chrusciel E, Urban-Wojciuk Z, Arcimowicz L, et al. Adoptive Cell Therapy-Harnessing Antigen-Specific
516 T Cells to Target Solid Tumours. *Cancers (Basel)* 2020;12(3) doi: 10.3390/cancers12030683
- 517 3. Oppermans N, Kueberuwa G, Hawkins RE, et al. Transgenic T-cell receptor immunotherapy for cancer:
518 building on clinical success. *Ther Adv Vaccines Immunother* 2020;8:2515135520933509. doi:
519 10.1177/2515135520933509
- 520 4. Janelle V, Carli C, Taillefer J, et al. Defining novel parameters for the optimal priming and expansion of
521 minor histocompatibility antigen-specific T cells in culture. *Journal of translational medicine*
522 2015;13:123. doi: 10.1186/s12967-015-0495-z
- 523 5. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumor T cell. *Nat*
524 *Rev Cancer* 2012;12(10):671-84. doi: nrc3322 [pii]
10.1038/nrc3322 [published Online First: 2012/09/22]
- 525 6. Janelle V, Delisle JS. T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts
526 and Mitigation Strategies. *Cancers (Basel)* 2021;13(4) doi: 10.3390/cancers13040598
- 527 7. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
528 *Cancer Discov* 2018;8(9):1069-86. doi: 10.1158/2159-8290.CD-18-0367
- 529 8. Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer
530 immunotherapy. *Int J Clin Oncol* 2020 doi: 10.1007/s10147-019-01588-7
- 531 9. Vaddepally RK, Kharel P, Pandey R, et al. Review of Indications of FDA-Approved Immune Checkpoint
532 Inhibitors per NCCN Guidelines with the Level of Evidence. *Cancers (Basel)* 2020;12(3) doi:
533 10.3390/cancers12030738 [published Online First: 2020/04/05]
- 534 10. Schnell A, Bod L, Madi A, et al. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity
535 without autoimmunity. *Cell Res* 2020;30(4):285-99. doi: 10.1038/s41422-020-0277-x
- 536 11. Hobo W, Maas F, Adisty N, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments
537 expansion and function of minor histocompatibility antigen-specific CD8+ T cells. *Blood*
538 2010;116(22):4501-11. doi: 10.1182/blood-2010-04-278739
- 539 12. Boudreau G, Carli C, Lamarche C, et al. Leukoreduction system chambers are a reliable cellular source
540 for the manufacturing of T-cell therapeutics. *Transfusion* 2019;59(4):1300-11. doi:
541 10.1111/trf.15121
- 542 13. Orio J, Carli C, Janelle V, et al. Early exposure to interleukin-21 limits rapidly generated anti-Epstein-
543 Barr virus T-cell line differentiation. *Cytotherapy* 2015;17(4):496-508. doi:
544 10.1016/j.jcyt.2014.12.009
- 545 14. Dahmani A, Janelle V, Carli C, et al. TGFbeta Programs Central Memory Differentiation in Ex Vivo-
546 Stimulated Human T Cells. *Cancer Immunol Res* 2019;7(9):1426-39. doi: 10.1158/2326-6066.CIR-
547 18-0691
- 548 15. Wolf FA, Angerer P, Theis FJ. SCANPY: large-scale single-cell gene expression data analysis. *Genome*
549 *Biol* 2018;19(1):15. doi: 10.1186/s13059-017-1382-0
- 550 16. Levine JH, Simonds EF, Bendall SC, et al. Data-Driven Phenotypic Dissection of AML Reveals
551 Progenitor-like Cells that Correlate with Prognosis. *Cell* 2015;162(1):184-97. doi:
552 10.1016/j.cell.2015.05.047
- 553 17. Nazarov VI, Pogorelyy MV, Komech EA, et al. tcR: an R package for T cell receptor repertoire advanced
554 data analysis. *BMC Bioinformatics* 2015;16:175. doi: 10.1186/s12859-015-0613-1
- 555 18. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell
556 exhaustion phenotype in mice with disseminated acute myelogenous leukemia. *Blood*
557 2011;117(17):4501-10. doi: 10.1182/blood-2010-10-310425
- 558 19. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell
559 exhaustion and restore anti-tumor immunity. *J Exp Med* 2010;207(10):2187-94. doi:
560 10.1084/jem.20100643 [published Online First: 2010/09/08]
- 561 20. Tan J, Yu Z, Huang J, et al. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence
562 the clinical outcome of patients with AML. *Biomark Res* 2020;8:6. doi: 10.1186/s40364-020-0185-
563 8
564

- 565 21. Gorman JV, Starbeck-Miller G, Pham NL, et al. Tim-3 directly enhances CD8 T cell responses to acute
566 *Listeria monocytogenes* infection. *J Immunol* 2014;192(7):3133-42. doi:
567 10.4049/jimmunol.1302290
- 568 22. Azizi E, Carr AJ, Plitas G, et al. Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor
569 Microenvironment. *Cell* 2018;174(5):1293-308 e36. doi: 10.1016/j.cell.2018.05.060
- 570 23. Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease. *Annu*
571 *Rev Immunol* 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326
- 572 24. Schmiech S, Gostick E, Price DA, et al. Analysis of the functional WT1-specific T-cell repertoire in healthy
573 donors reveals a discrepancy between CD4(+) and CD8(+) memory formation. *Immunology*
574 2015;145(4):558-69. doi: 10.1111/imm.12472
- 575 25. Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-Reactive CD8+ T Cells Can Mediate
576 Antileukemic Activity and Persist in Post-Transplant Patients. *Sci Transl Med* 2013;5(174):174ra27.
577 doi: 5/174/174ra27 [pii]
- 578 10.1126/scitranslmed.3004916 [published Online First: 2013/03/01]
- 579 26. Doubrovina E, Carpenter T, Pankov D, et al. Mapping of novel peptides of WT-1 and presenting HLA
580 alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+)
581 leukemias. *Blood* 2012;120(8):1633-46. doi: blood-2011-11-394619 [pii]
- 582 10.1182/blood-2011-11-394619 [published Online First: 2012/05/25]
- 583 27. Sun F, Guo ZS, Gregory AD, et al. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic
584 virotherapy in refractory lung cancer. *J Immunother Cancer* 2020;8(1) doi: 10.1136/jitc-2019-
585 000294
- 586 28. Lee J, Su EW, Zhu C, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling
587 pathways. *Mol Cell Biol* 2011;31(19):3963-74. doi: 10.1128/MCB.05297-11
- 588 29. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. *Immunol Rev*
589 2017;276(1):97-111. doi: 10.1111/imr.12520
- 590 30. Ahn E, Araki K, Hashimoto M, et al. Role of PD-1 during effector CD8 T cell differentiation. *Proc Natl*
591 *Acad Sci U S A* 2018;115(18):4749-54. doi: 10.1073/pnas.1718217115
- 592 31. Odorizzi PM, Pauken KE, Paley MA, et al. Genetic absence of PD-1 promotes accumulation of
593 terminally differentiated exhausted CD8+ T cells. *J Exp Med* 2015;212(7):1125-37. doi:
594 10.1084/jem.20142237
- 595 32. Friese C, Harbst K, Borch TH, et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+)
596 tumor-infiltrating lymphocytes in ovarian cancer. *Sci Rep* 2020;10(1):3914. doi: 10.1038/s41598-
597 020-60738-4
- 598 33. Rudqvist NP, Pilonis KA, Lhuillier C, et al. Radiotherapy and CTLA-4 Blockade Shape the TCR
599 Repertoire of Tumor-Infiltrating T Cells. *Cancer Immunol Res* 2018;6(2):139-50. doi: 10.1158/2326-
600 6066.CIR-17-0134
- 601 34. Han J, Duan J, Bai H, et al. TCR Repertoire Diversity of Peripheral PD-1(+)/CD8(+) T Cells Predicts
602 Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. *Cancer*
603 *Immunol Res* 2020;8(1):146-54. doi: 10.1158/2326-6066.CIR-19-0398

605 **Figures**


Figure 1



607 **Figure 1. Repeated antigenic encounters ex vivo leads to antigen-specific T-cell exhaustion.** (A)
608 Representative fluorescent multimer staining of LMP2₄₂₆₋₄₃₄-specific CD8⁺ T cells (LMP2) and total cellular
609 expansion (expressed as fold change relative to culture input – 15x10⁶ cells). (B) Percentages, as well as
610 (C) calculated number of antigen-specific T cells at the indicated time points (n=10 different donors). (D)
611 Representative staining to determine naïve (T_n), central memory (T_{cm}), effector memory (T_{em}), and
612 effector T cells (T_{eff}) and the percentage of HLA-A02/LMP2₄₂₆₋₄₃₄ multimer positive CD8⁺ T cells within
613 these categories at different culture time points (n= 12 different donors). (E) Representative histograms of
614 immune checkpoint expression evaluated relative to fluorescence minus one (FMO) control in HLA-A0201-
615 LMP2₄₂₆₋₄₃₄ (LMP2) multimer-stained T cells and compiled results from 12 different donors. (F)
616 Representative staining of PD-1 and TIM-3 co-expression and compiled results from 9-13 different donors.
617 (H) Percentage expression of PD-1 and TIM-3 ligands on dendritic cells used to stimulate T cells (n=5
618 different donors). Significant p values are indicated on figure panels. All error bars represent standard
619 deviation to the mean (SEM).

620

Figure 2



621

622 **Figure 2. Dual but not single PD-L1 and TIM-3 blockade improves T-cell expansion.** (A) Total cell

623 expansion relative to input at the beginning of the culture in function of time and culture condition; no

624 blocking antibodies (ctrl), anti-PD-L1 (α-PD-L1), anti-TIM3 (α-TIM3) or both (double blockade - DB).

625 Absolute count (B) and percentage (C) of HLA-A0201-LMP2₄₂₆₋₄₃₄ (LMP2) multimer positive T cells in the

626 same conditions and at the same time-points. (D) T-cell differentiation phenotypes; naïve (Tn), central

627 memory (Tcm), effector memory (Tem) and effector T cells (Teff) and (E) percentages of LMP2 multimer

628 positive T cells expressing immune checkpoints in the function of culture conditions and time-points (n=4-


629 10 different donors). Significant (<0.05) p-values are indicated on the figure panels. All error bars represent

630 SEM.

631

632

Figure 3



633

634 **Figure 3. Delayed double blockade (DDB) further improves T-cell yield.** (A) Total T-cell expansion

635 relative to input at day 0 in the function of time and culture condition; no blocking antibodies (Ctrl), double

636 anti-PD-L1 and anti-TIM-3 applied at culture initiation (double blockade – DB), anti-PD-L1 introduced at day

637 0 and anti-TIM-3 introduced at day 7 (delayed double blockade – DDB). (B) Percentages and (C) absolute

638 counts of HLA-A0201-LMP2₄₂₆₋₄₃₄ (LMP2) multimer positive T cells from the same cultures. (D) T-cell


639 differentiation phenotypes and (E) immune checkpoint expression of LMP2 multimer positive cells in the

640 same culture conditions and time-points (n=8 different donors). Significant (<0.05) p-values are indicated

641 on the figure panels. All error bars represent SEM.

642


Figure 4



643
 644 **Figure 4. DDB expands a high proportion and number of functional antigen-specific T cells.** (A)
 645 Representative dot plots showing intracellular cytokine secretion following LMP2₄₂₆₋₄₃₄ antigenic re-
 646 stimulation at day 28 and compiled results from 6 independent donor cultures; expansion with no blocking
 647 antibodies (CTRL), anti-PD-L1 and anti-TIM3 antibodies both introduced at the beginning of the culture

648 (DB) or both antibodies but anti-TIM3 introduced at day 7 (DDB). (B) IFN- γ ELISpot results using 50,000
649 cells per condition harvested from the cultures at the indicated time-points and using the following
650 stimulating conditions: vehicle only (DMSO), anti-CD3 (CD3, positive control), irrelevant peptide (Irr.),
651 LMP2₄₂₆₋₄₃₄ peptide (LMP2). (C) Percentage of Ki-67 staining at day 28 among CD8⁺ T cells from the ctrl
652 vs DDB cultures (n=5 different donors) and (D) co-expression of surface CD107a and intracellular
653 granzyme-b (GzB) as surrogate for degranulation following LMP2₄₂₆₋₄₃₄ exposure. (E) Fluorescence-based
654 cytotoxicity assay (cell tracer yellow – CTY or cell tracer violet – CTV) showing loss of targets loaded
655 (LMP2+) or not (LMP2-) with the LMP2₄₂₆₋₄₃₄ antigen (numbers indicate percentages of total events) and
656 (F) compiled results at different target:T-cell ratio (from 3 different donors). The significant p-values are
657 indicated on the panels and error bars indicate SEM.
658

Figure 5



659

660 **Figure 5. Single-cell RNA-sequencing of antigen-specific T cells after double immune checkpoint**
661 **inhibition.**


662 (A) T-stochastic neighbor embedding (t-SNE) of normalized single-cell gene expression after dimensionality
663 reduction from control (CTRL) and delayed double blockade (DDB) conditions, color coded by donor and
664 experimental condition (CTRL, DDB). (B) Dot plot representing the change in the expression of genes
665 related to pathways of interest in the DDB condition compared to the CTRL condition. The color of the dots
666 represents the log₂ fold-change of the genes in the pathway and the size of the dot is representative of the

667 percentile ranking of the comparison in random gene sets (see Methods). (C) Clonotype frequencies in the
668 CTRL and DDB conditions for each donor. (D) Similar to (B) comparing the cells of selected
669 clonotypes/patients between the two experimental conditions. The donor of origin is color coded.

670

671

Figure 6



672

673 **Figure 6. Impact of DDB on clonal diversity and stability in time.**

674 (A) Estimate of TCR repertoire diversity using the Gini-Simpson index among HLA-multimer negative and

675 positive T cells at day 21 and 28. (B) Clonal hierarchy and clonal relatedness among

676 HLA-A0201-LMP2₄₂₆₋₄₃₄ multimer positive T cells between day 21 and 28 based on the day 28 repertoire in

677 the DDB (B) or control condition (C) based on bulk CDR3 sequencing. The control condition in Donor 3 was

678 not assessed due poor RNA quality at day 28. (D) Dot plot representing the change in the expression of


679 genes related to pathways of interest when comparing a clonotype of interest in a donor/experimental

680 condition to all the other clonotypes in the same donor/condition. The clonotypes selected are those whose

681 abundance vary by more than 20% between day 21 and 28.

682

Figure 7



683

684 **Figure 7. Improved expansion of functional WT1-specific T cells with DDB.** (A) Representative HLA-
 685 A0201-WT1₃₇₋₄₅ multimer staining (WT1) of CD8⁺ T cells. (B) Cell expansion expressed as fold increase
 686 relative to cell input at the beginning of the culture (15×10^6) in ctrl (no blocking antibodies) or delayed double
 687 anti-PD-L1 and anti-TIM3 blockade (DDB) condition, as well as percentage (C) and absolute numbers (D)
 688 of WT1-specific T cells at different time-points in culture. (E) Proportion of intracellular cytokine expression
 689 following WT1 exposure at day 28 of the culture in CD8⁺ cells and (F) IFN- γ ELISpot results at days 14, 21,
 690 and 28 of culture following exposure to vehicle alone (DMSO), a peptide not used in the culture (irrelevant,

691 Irr) as negative controls, anti-CD3 ϵ (positive control) and the targeted peptide (WT1). (G) T-cell
692 differentiation; naïve (Tn), central memory (Tcm), effector memory (Tem), and effector T cells (Teff) and
693 (H) percentage of immune checkpoint surface expression on WT-1 specific T cells. Four (4) different
694 donors, p-values are indicated on the figures, error bars indicate SEM.
695